Broadfin Capital and Bridger Management Think SeaSpine Holdings Corp (SPNE) Is Oversold

Page 2 of 2

However, there are some industry characteristics that might inhibit the company’s rapid growth. According to iData Research, the expected annual growth for the Orthobiologics market from 2014 to 2021 is only 3.4%, and for the spinal Fusion Hardware market the growth figure is even lower at just 0.7%. Thus it is not surprising that since its IPO on June 19, SeaSpine Holdings Corp (NASDAQ:SPNE)’s stock has fallen by about 15%. However, Broadfin Capital and Bridger Management’s latest move might suggest that this presents a great entry point, especially considering that the company currently only has 18% market share in the orthobiologics segment.

Follow Roberto Mignone's Bridger Management

Hedge funds have been enthusiastic about Integra Lifesciences Holdings Corp (NASDAQ:IART), especially during the first quarter when SeaSpine Holdings Corp (NASDAQ:SPNE) was part of its business. Among the funds that we track, 13 had an aggregate investment of $73.78 million in Integra Lifesciences Holdings Corp (NASDAQ:IART) at the end of March, compared to seven firms with $33.43 million in shares at the end of the previous quarter. The largest investors of Integra Lifesciences among the funds we track, as of March 31, were Ken Fisher‘s Fisher Asset Management and Paul Tudor Jones’ Tudor Investment Corp, with respective holdings amounting to 520,200 shares valued at $32.07 million and 200,000 shares valued at $12.33 million.

Disclosure: None

Page 2 of 2